Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
about
Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.Molecular Testing of Brain Tumor.Comparative transcriptome analysis of isogenic cell line models and primary cancers links capicua (CIC) loss to activation of the MAPK signalling cascadeCancer metabolism as a central driving force of glioma pathogenesisMGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma responseIDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.Novel Anthropometry Based on 3D-Bodyscans Applied to a Large Population Based Cohort.Combination genetic signature stratifies lower-grade gliomas better than histological grade.Isocitrate dehydrogenase mutations in gliomasPI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patientsHigh expression of VEGF and PI3K in glioma stem cells provides new criteria for the grading of gliomas.miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas.Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients.Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomasEstablishment of Anti-Human ATRX Monoclonal Antibody AMab-6.Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.Molecular profiling of gliomas: potential therapeutic implications.Circulating biomarkers for gliomas.Advances in the molecular genetics of gliomas - implications for classification and therapy.Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.DNA methylation in adult diffuse gliomas.The Role of Molecular Diagnostics in the Management of Patients with Gliomas.The new WHO 2016 classification of brain tumors-what neurosurgeons need to know.Prognostic relevance of miRNA-155 methylation in anaplastic glioma.Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomasMolecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel.Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers.Epigenetic Heterogeneity of B-Cell Lymphoma: DNA Methylation, Gene Expression and Chromatin States.Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.PET imaging in glioma: is it time for mainstream practice?A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics.Glioma.Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas.Overexpression of COX7A2 is associated with a good prognosis in patients with glioma.Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis.Salvage stereotactic radiosurgery for recurrent gliomas with prior radiation therapy.Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.Neurological update: gliomas and other primary brain tumours in adults.
P2860
Q33711322-1A769CDE-BD85-48A0-9D4E-6F4C4E5474DEQ33729693-BA21D63E-C992-41A2-82AA-4B2FC4FF7222Q33835854-5FD5F9EA-F023-4C67-B767-CBD0F679375AQ33847616-399DA0B6-471A-4229-81E4-7CC2D747AD3DQ34525704-B5C7108D-3865-4984-BFA9-4528DBB7352CQ35845197-CB105516-FE13-4E75-AC3D-DCB8D3298D69Q36088670-51B514CB-EC2A-483A-B054-04B0108ADB63Q36356194-F2CAD9DC-53DC-4DB0-A267-34F76339AACAQ36367409-DE412D78-23B6-4FB6-98A1-5DAC9C6D45E3Q36402259-ED51EFBD-DA70-4FD1-BA9A-FCD3BB1ED4A1Q36524261-D02CBFBF-1168-4567-A296-7719A7227E64Q36557234-4D991B52-5E69-4AFD-BB8B-40DDD768B5F6Q36774118-F4F424CC-FF27-4667-A9BC-1FD184A7328CQ36785136-02574B09-4E19-46F2-9A6F-CAD579A5C234Q37509161-C61B19A4-E6C4-4F1A-A4F3-636FF67031BBQ37662100-E3BAD3C5-DD25-4F2E-9BDA-5AC525E69030Q38390616-F35A44F1-6EFC-46B5-9D20-2F4FDBA0ACC3Q38539422-0F749A37-2F97-402F-AA2B-1E6BB47DFD04Q38586617-E4BC89F1-CCCE-4724-959F-D11C5AB6DB63Q38777058-5D944974-B7F1-4803-B86D-664BC8DAA764Q38816272-038B8770-7849-4275-9909-776F6DA79612Q38861997-68ADF81A-FCBA-48A7-8991-60E22E6134A1Q38921975-5354562D-3851-4EB5-93F3-B94CEBFDD4D4Q39091307-A7C9CDDC-34FD-4220-966B-2D31D4BFB286Q39158460-E0EA3410-6308-4CC3-84C1-99923305E06CQ39937053-94C3299E-DD86-433D-8EC6-FF9E13A129EBQ39965737-87F9F1A4-18F7-43F1-941A-7AF1C3C2CF63Q40387247-B7D20778-8559-4F1D-AD6A-37E4348BF41AQ40539026-CB06A804-5652-4060-B85C-0CE6F938AFBBQ40560920-02EECED2-AD85-402B-8164-67BF435C957CQ40822804-E6D67A20-931A-434D-9999-C1A6AEAC2B92Q42332774-DF5A1D45-D0EC-4E04-9B7E-25DBD36FCB31Q44457966-84FEC8FF-72CC-4591-ABCB-3EC862061739Q46820292-F6CF6CF5-3CA8-42FB-928E-0A70F704A18EQ47369186-6C0F0805-D877-49DF-9551-4EA4B8E54117Q47729454-1A9A57B3-E8FC-4613-A285-997E76D73640Q47797453-A95024A0-8C75-4E68-A3DC-0CBBA5B7497AQ47805151-F61598E8-9324-48AE-84DB-B359789F4DD3Q47860829-2186AAD2-3D32-44C6-AC18-86F95C21BE6FQ47989137-DD0D9233-F134-40BE-9F1B-F205F8B02AD4
P2860
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Molecular classification of di ...... cally distinct patient groups.
@en
type
label
Molecular classification of di ...... cally distinct patient groups.
@en
prefLabel
Molecular classification of di ...... cally distinct patient groups.
@en
P2093
P2860
P50
P921
P1476
Molecular classification of di ...... cally distinct patient groups.
@en
P2093
Bettina Hentschel
Christian Hagel
Christian Hartmann
Dietmar Krex
Dorothee Gramatzki
Edith Willscher
Gabriele Schackert
Hans Binder
Henry Löffler-Wirth
Jan Boström
P2860
P2888
P304
P356
10.1007/S00401-015-1409-0
P50
P577
2015-03-18T00:00:00Z